Treatment patterns and clinical outcomes in hospitalized adults with discordant Clostridioides difficile results: a multihospital cohort study
Year: 2026
Type: article
Abstract: Clostridioides difficile infection (CDI) is a common gastrointestinal infection in hospitalized patients. A two-step testing algorithm comprised of a nucleic acid amplification test (NAAT) followed by a specific toxin assay may be used to improve diagnostic accuracy of infection testing. Discordant results (NAAT+/Toxin-), however, create clinical uncertainty regarding the administration of CDI antimicrobial therapy. The purpose of this retrospective cohort study was to identify predictors of adverse clinical outcomes, including administration of CDI antimicrobial therapy as a primary predictor of interest, and evaluate treatment patterns among hospitalized adults with discordant C. difficile test results. This study included hospitalized adults with discordant (NAAT+/Toxin-) C. difficile test results between December 2023 and June 2025 across a nine-hospital tertiary-care health system. The primary outcome was a composite endpoint of 30-day all-cause mortality and colectomy attributable to C. difficile. Secondary outcomes included receipt of CDI antimicrobial therapy and 30-day all-cause readmission to an acute-care facility. Multivariable logistic regression identified factors associated with clinical outcomes and antimicrobial therapy. Among 1,256 patients with discordant C. difficile testing, the primary composite outcome occurred in 59 (5%) patients. Factors associated with the primary outcome included older age (65–99 years; odds ratio (OR) 2.95, [1.53–6.20], p < 0.01), immunocompromised status within 30 days prior to the discordant test (OR 2.08, [1.10–4.15], p = 0.03), white blood cell counts ≥ 15,000 cells/µL (OR 1.86, [1.05–3.26], p = 0.03), and intensive care unit (ICU) status at the time of the C. difficile discordant test (OR 3.49, [1.91–6.29], p < 0.01). Overall, 879 (70%) patients received antimicrobial therapy; in exploratory analyses, ICU status was associated with treatment receipt (OR 1.50, 95% CI 1.02–2.24). Thirty-day readmission was associated with immunocompromised status (OR 1.68, 95% CI 1.25–2.26), elevated creatinine levels (OR 1.48, 95% CI 1.12–1.96), and higher comorbidity index (OR 2.03, 95% CI 1.34–3.14), and older age was associated with lower odds of readmission (OR 0.75, 95% CI 0.57–0.99). Patient-level clinical characteristics and markers of acute illness, rather than discordant CDI test results alone, are more strongly associated with short-term clinical outcomes. CDI antimicrobial therapy was not independently associated with the primary composite outcome among patients with discordant C. difficile test results after adjustment for measured confounders. Future studies are needed to determine whether specific groups of patients with discordant results benefit from treatment.
Source: Scientific Reports
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,690
OpenAlex ID: W7237347553
FWCI:
Cites:
Cited by:
Related to:
